Related Experiment Video
Updated: Aug 6, 2026
Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Thrombocytopenia in term infants: a population-based study
S Sainio1, A L Järvenpää, M Renlund
1Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Insights
Severe neonatal thrombocytopenia in full-term infants is often caused by alloimmune thrombocytopenia. Immunologic studies are crucial for managing this condition and preventing future complications.
Area of Science:
- Neonatal Medicine
- Immunology
- Pediatric Hematology
Background:
- Thrombocytopenia, a low platelet count, affects newborns and can have serious consequences.
- Identifying the causes of thrombocytopenia is essential for appropriate management and prognosis.
Purpose of the Study:
- To determine the prevalence and etiological factors of thrombocytopenia in full-term infants.
- To investigate the role of alloimmune thrombocytopenia in neonatal cases.
Main Methods:
- A 1-year population-based surveillance study of full-term infants in Helsinki.
- Cord blood platelet counts were analyzed, with clinical evaluation and immunologic studies for affected infants and parents.
Main Results:
- The prevalence of thrombocytopenia (platelet count < 150 x 10(9)/L) was 2.0% in 4,489 infants.
- Severe thrombocytopenia (< 50 x 10(9)/L) occurred in 0.24% of infants.
- Fetomaternal alloimmune thrombocytopenia was the cause of all clinically significant cases, with an incidence of 1 in 1500 live births.
Conclusions:
- Immunologic evaluation is recommended for all cases of severe neonatal thrombocytopenia.
- Early diagnosis and monitoring can prevent severe complications in affected infants and guide management in subsequent pregnancies.
Objective:
To assess the prevalence and causes of thrombocytopenia among full-term infants.
Methods:
We conducted a 1-year, population-based surveillance study involving all full-term infants (at least 37 weeks' gestation) born to native Finnish women in Helsinki. In cases of thrombocytopenia (cord platelet count less than 150 x 10(9)/L) clinical risk factors were evaluated and immunologic studies were performed on both parents and on the infant; 95% confidence intervals (CIs) were calculated on the basis of binomial distribution.
Results:
Platelet counts were done in cord blood from 4,489 infants, 84.9% of the study population. Eighty-nine infants had platelet counts below 150 x 10(9)/L (2.0%; 95% CI 1.5, 2.3) in cord blood and 11 were less than 50 x 10(9)/L (0.24%; 95% CI 0.10, 0.38). All causes of clinically important thrombocytopenia, those presenting with bleeding and requiring treatment, were related to fetomaternal alloimmune thrombocytopenia. The incidence of severe alloimmune thrombocytopenia was one in 1500 live births and one in 900 of all thrombocytopenia. An immunologic mechanism was involved in ten of 65 (15.4%; 95% CI 6.6, 24.2) infants studied and in four of 15 (26.7%; 95% CI 4.3, 49.1) cases of severe thrombocytopenia.
Conclusion:
Immunologic studies should be considered in all cases of severe neonatal thrombocytopenia for careful monitoring and prevention of potentially severe complications in subsequent pregnancies.
